Sukeshi Arora is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 138 publications with 1,340 citations (h-index 17); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7979 Wurzbach Rd
San Antonio, TX 782294427
Telephone
210-450-1143Registry record last updated 28 Feb 2018.
Clinical trials
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Sponsor: The University of Texas Health Science Center at San Antonio
- Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Sponsor: The University of Texas Health Science Center at San Antonio
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Sponsor: The University of Texas Health Science Center at San Antonio
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202514 payments$21,431openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- PFIZER INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55.4%Other antiemetics42.8%Fosaprepitant100%Part B, office-administered≥17 patientsSerotonin-3 Receptor Antagonist9.7%Ondansetron hydrochloride62%Palonosetron hcl31%Ondansetron Hcl4%Ondansetron Odt3%Part D + Part B≥27 patients+ 6 more classes in this area
Musculoskeletal
31.1%RANK Ligand Inhibitor31.1%Denosumab100%Part B, office-administered≥15 patientsSensory organs
9.1%Corticosteroid9.1%Dexamethasone sodium phosphate97%Dexamethasone3%Part D + Part B≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”